368 related articles for article (PubMed ID: 16580110)
1. Risperidone in the treatment of psychotic depression.
Goto M; Yoshimura R; Kakihara S; Shinkai K; Yamada Y; Kaji K; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110
[TBL] [Abstract][Full Text] [Related]
2. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders.
Yoshimura R; Nakano Y; Hori H; Ikenouchi A; Ueda N; Nakamura J
Hum Psychopharmacol; 2006 Oct; 21(7):433-8. PubMed ID: 17029305
[TBL] [Abstract][Full Text] [Related]
3. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
4. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study.
Vieta E; Goikolea JM; Corbella B; Benabarre A; Reinares M; Martínez G; Fernández A; Colom F; Martínez-Arán A; Torrent C;
J Clin Psychiatry; 2001 Oct; 62(10):818-25. PubMed ID: 11816872
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Yoshimura R; Shinkai K; Ueda N; Nakamura J
Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
[TBL] [Abstract][Full Text] [Related]
6. Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline.
Yoshimura R; Umene-Nakano W; Ueda N; Ikenouchi-Sugita A; Hori H; Nakamura J
Hum Psychopharmacol; 2008 Dec; 23(8):707-13. PubMed ID: 18803170
[TBL] [Abstract][Full Text] [Related]
7. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression.
Yoshimura R; Ikenouchi-Sugita A; Hori H; Umene-Nakano W; Katsuki A; Hayashi K; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):308-12. PubMed ID: 20005280
[TBL] [Abstract][Full Text] [Related]
8. [Risperidone in the early treatment of first-episode psychosis: a two-year follow-up study].
Gutiérrez Fraile M; Segarra Echevarría R; González-Pinto Arrillaga A; Martínez Junquera G
Actas Esp Psiquiatr; 2002; 30(3):142-52. PubMed ID: 12106515
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
Rothschild AJ; Samson JA; Bessette MP; Carter-Campbell JT
J Clin Psychiatry; 1993 Sep; 54(9):338-42. PubMed ID: 8104930
[TBL] [Abstract][Full Text] [Related]
10. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors.
Yukimasa T; Yoshimura R; Tamagawa A; Uozumi T; Shinkai K; Ueda N; Tsuji S; Nakamura J
Pharmacopsychiatry; 2006 Mar; 39(2):52-9. PubMed ID: 16555165
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of imipramine in psychotic versus nonpsychotic depression.
Birkenhager TK; van den Broek WW; Mulder PG; Moleman P; Bruijn JA
J Clin Psychopharmacol; 2008 Apr; 28(2):166-70. PubMed ID: 18344726
[TBL] [Abstract][Full Text] [Related]
12. Two cases of bipolar disorder successfully stabilized for five years with a low dose of risperidone and lithium.
Yoshimura R; Ueda N; Shinkai K; Nakamura J
Pharmacopsychiatry; 2006 Nov; 39(6):233-4. PubMed ID: 17124648
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M
J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression.
Politis AM; Papadimitriou GN; Theleritis CG; Psarros C; Soldatos CR
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1227-30. PubMed ID: 18442877
[TBL] [Abstract][Full Text] [Related]
15. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
16. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
19. Long-acting risperidone in stable patients with schizoaffective disorder.
Mohl A; Westlye K; Opjordsmoen S; Lex A; Schreiner A; Benoit M; Bräunig P; Medori R
J Psychopharmacol; 2005 Sep; 19(5 Suppl):22-31. PubMed ID: 16144783
[TBL] [Abstract][Full Text] [Related]
20. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
